Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:45:19 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:JNJ from 2023-04-30 to 2024-04-29 - 54 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
2024-04-20 01:28U:JNJSEDAR Annual ReportSEDAR MD & A
2024-04-16 06:25U:JNJNews ReleaseJohnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
2024-04-16 03:20U:JNJNews ReleaseCORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
2024-04-08 18:06U:JNJNews ReleaseJohnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
2024-04-05 23:21U:JNJNews ReleaseCARVYKTI(TM) is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
2024-04-05 06:31U:JNJNews ReleaseJohnson & Johnson to Acquire Shockwave Medical
2024-04-04 18:01U:JNJNews ReleaseJohnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation
2024-04-02 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the BofA Securities Health Care Conference
2024-03-12 09:15U:JNJNews ReleaseArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
2024-03-11 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on First-Quarter Results
2024-03-07 08:33U:JNJNews ReleaseJohnson & Johnson Completes Acquisition of Ambrx
2024-03-01 15:59U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2024-02-20 16:26U:JNJNews ReleaseTECVAYLI ‚ ® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
2024-02-14 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-02-12 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Leerink Global Biopharma Conference
2024-02-02 16:10U:JNJNews ReleaseJohnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-01-24 15:42U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-01-23 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q4 and Full-Year 2023 Results
2024-01-08 07:30U:JNJNews ReleaseJohnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
2024-01-02 08:00U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for First Quarter 2024
2023-12-19 12:05U:JNJSEDAR Interim MD & ASEDAR Interim MD & A
2023-12-12 11:40U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-12-11 16:15U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
2023-12-07 16:15U:JNJNews ReleaseJohnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 13:31U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-12-05 07:15U:JNJNews ReleaseJohnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review
2023-11-30 16:30U:JNJNews ReleaseJohnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
2023-11-30 08:40U:JNJNews ReleaseJohnson & Johnson MedTech Acquires Laminar, Inc.
2023-11-16 07:30U:JNJNews ReleaseJohnson & Johnson to Host Enterprise Business Review
2023-10-23 16:15U:JNJNews ReleaseJohnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
2023-10-19 13:43U:JNJNews ReleaseJohnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023
2023-10-17 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q3 2023 Results
2023-09-18 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Third-Quarter Results
2023-09-14 10:00U:JNJNews ReleaseJohnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
2023-08-30 06:30U:JNJNews ReleaseJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
2023-08-23 06:20U:JNJNews ReleaseJohnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
2023-08-22 10:24U:JNJNews ReleaseJohnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-21 18:01U:JNJNews ReleaseKenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600
2023-08-21 06:20U:JNJNews ReleaseJohnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
2023-08-16 18:52U:JNJNews ReleaseJohnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.
2023-08-10 18:58U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-09 18:58U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-09 18:42U:JNJNews ReleaseKenvue Set to Join S&P 500
2023-08-08 18:58U:JNJSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-07 19:29U:JNJNews ReleaseJohnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference
2023-07-24 06:22U:JNJNews ReleaseKenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
2023-07-24 06:18U:JNJNews ReleaseJohnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
2023-07-20 06:20U:JNJNews ReleaseJohnson & Johnson Reports Q2 2023 Results
2023-07-10 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit
2023-06-12 03:00U:JNJNews ReleaseAlvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ®
2023-06-06 16:30U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2023-05-10 16:30U:JNJNews ReleaseJohnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-03 19:22U:JNJNews ReleaseJohnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering